MedTrace Logo

Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma

NCT06310590 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-03

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of NRT6003 Injection in patients with unresectable HCC.

Conditions

Interventions

DRUG

NRT6003 Injection

Selective internal radiation therapy (SIRT) with TareSphere

Sponsors & Collaborators

  • Chengdu New Radiomedicine Technology Co. LTD.

    lead INDUSTRY

Principal Investigators

  • Gaojun Teng, MD · Zhongda Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-08
Primary Completion
2025-06-10
Completion
2025-06-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06310590 on ClinicalTrials.gov